Global Healthcare Analyst

Tina Banerjee

Equity research analyst having 15+ years of experience, with an interest on fundamentally strong global healthcare companies. I have been helping investors to find future winners in healthcare space to grow their wealth by focusing on the strength and potential of the business models of the companies. My initiating coverage reports and pitch help investors to know ‘what to buy’, ‘why to buy’, and ‘when to buy’. My clients always remain on top of the sector with the help of my timely and detailed notes on earnings or any news update. I also provide broader view on the entire healthcare sector through periodic thematic reports.

Classys (214150 KS): Stellar 3Q Result; 2025 Guidance Reaffirmed; Brazil Is Set to Recover from 4Q

Classys (214150 KS): 2024 Sales Beat Guidance; New Record Sales Target for 2025

Classys (214150 KS): Record High Sales in 3Q24; Volnewmer Led Performance Growth; US Launch Begins

Classys (214150 KS): Solid Start to 2025; Global Expansion Continues; Stake Sale Overhang to Remain

Classys: Block Deal Sale of 6% By Bain Capital Raises Overhang Concerns

Equity Bottom-Up

<ul>
<li>
<a href="https://www.smartkarma.com/entities/classys" target="_blank" data-smartkarma-citation="entities:29688:1" rel="noopener">Classys (214150 KS)</a> has reported strong 2Q25 result, with record high quarterly sales, gross profit, and operating profit. In fact, revenue hit sixth consecutive quarterly record high.</li>
<li>During 2Q25, revenue from device increased 47% YoY and 30% QoQ to KRW46B, mainly driven by strong global sales, which increased 36% YoY and 27% QoQ to KRW33B.</li>
<li>Classys reaffirmed 2025 revenue guidance of KRW340–360B, up 39–48% YoY. In 1H25, the company has achieved 46% of annual revenue target, thereby enhancing guidance visibility.</li>
</ul>



Classys (214150 KS) has reported strong 2Q25 result, with record high quarterly sales, gross profit, and operating profit. In fact, revenue hit sixth consecutive quarterly record high.
During 2Q25, revenue from device increased 47% YoY and 30% QoQ to KRW46B, mainly driven by strong global sales, which increased 36% YoY and 27% QoQ to KRW33B.
Classys reaffirmed 2025 revenue guidance of KRW340–360B, up 39–48% YoY. In 1H25, the company has achieved 46% of annual revenue target, thereby enhancing guidance visibility.


Classys (214150 KS): Equipment Sale Boosts 2Q Result; New Device Approval to Drive 2H Performance